[19] Spellman CW
Other AEs reported with SGLT2i use include osmotic diuresis-related events and volume depletion-related hypotension, the latter of which tends to be more common in older adults, people with an eGFR of 3060 mL/min/1.73 m 2 , and in those taking loop diuretics [4]
While many plans might not cover medications used solely for weight loss, they often do cover them if they're prescribed for related health issues like type 2 diabetes
To properly discuss these concerns, its important to first understand how GLP-1 drugs actually work
In early 2026, the FDA and MHRA (UK) reported a spike in unregulated, mass-compounded GLP-1s that were either sub-potent or contained dangerous contaminants
The medical takeaway is simple: retatrutide is not just another celebrity weight-loss trend. It is part of a larger movement toward more powerful incretin-based therapies that may change how obesity, metabolic disease, and body composition are treated